AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06619795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
Study NCT06619795 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
Study NCT06623552 — intervention group
Intervention type: OTHER
Intervention: Neck Pain and Disability Scale (NPDS)
Description: The Turkish version of the Neck Pain and Disability Scale (NPDS), developed by Wheeler et al., was used for individuals with neck pain. The severity of neck pain is evaluated on a 5-point Likert scale; where 0 indicates no pain and 4 indicates very severe pain. The score is higher in those with upper extremity symptoms.The cut-off value of this scale was set to 15 to detect disability-related neck pain.The cut-off value is mandatory to evaluate a patient or a particular group of patients for clinically significant neck pain by distinguishing it from insignificant pain
Study NCT06623552 — intervention group
Intervention type: OTHER
Intervention: Fonseca Anamnestic Index (FAI)
Description: It is a questionnaire consisting of 10 questions, including pain during the period, parafunctional habits, movement restriction, clicking, malocclusion, emotional stress.In this study, clinical signs relevant to each severity category of Fonseca's anamnestic index were used to detect the frequency of symptoms and to characterize the symptoms and clinical findings of TMD.The Turkish version of Fonseca's Anamnestic Index (FAI) questionnaire was used to assess the symptom severity.
Study NCT06623552 — intervention group
Intervention type: OTHER
Intervention: Evaluation of Jaw Functional Limitation
Description: The Jaw Functional Limitation Scale (JFLS) was developed as an 8-item scale for general functional limitation in the jaw. In the light of the obtained items and supporting psychometric data, it has been expanded and re-developed to include the verbal and non-verbal communication limitations that occur in a 20-item tool16 JFLS-20 is a tool with three structure contents (chewing, vertical mobility of jaw state and emotional and verbal statement) to evaluate functional state.Difficulty performing a determined task is graded from 0 (without limitation) to 10 (severe limitation). Higher scores are a more serious sign of functional limitation.
Study NCT02391935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cryomedium
Study NCT02391935 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: skin penetration of the needle without injection of liquid
Study NCT00422344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Sunitinib
Description: Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
Study NCT03350061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSY
Description: The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
Study NCT02529904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 - ATIV
Description: All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV.
Study NCT02409381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motore
Description: 250 mg
Study NCT02409381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alivium
Description: 600 mg
Study NCT03203759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospitalization
Description: See above
Study NCT03203759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional inpatient hospitalization
Description: See above
Study NCT03439215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
Study NCT00036491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2
Study NCT04511962 — intervention group
Intervention type: OTHER
Intervention: Tele-Pulmonary rehabilitation
Description: The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
Study NCT01437709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab (This arm is closed)
Description: Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
Study NCT01437709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ofatumumab + Bendamustine
Description: Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 \& 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
Study NCT00738881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00738881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT00370981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pagoclone
Study NCT00370981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pagoclone
Study NCT00477750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression
Study NCT00477750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression
Study NCT00477750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/m\^2, orally days 1-4 every 28 days until progression
Study NCT00278148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC2 weekly x 3 weeks
Study NCT02391935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: skin penetration of the needle without injection of liquid
Study NCT03687268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone HCl PR tablets
Description: oral administration
Study NCT03687268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT02342925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Description: 647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
Study NCT02342925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: Oral administration twice daily
Study NCT02342925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Single 850 mg dose of metformin
Study NCT01288781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
Study NCT01288781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
Study NCT03514862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Booster Training
Description: Four additional mindfulness booster sessions after the 4-week MBI program.
Study NCT03514862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Booster Training
Description: Four additional mindfulness booster sessions after the 4-week MBI program.
Study NCT03514862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Description: MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
Study NCT03514862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Practice
Description: 4 weeks of self-practice after the MBI training.
Study NCT00649389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: 40mg olmesartan medoxomil
Study NCT00649389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: 40mg olmesartan medoxomil
Study NCT00649389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 10mg
Study NCT00649389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 10mg
Study NCT00649389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg
Study NCT03326193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (>=) 77 kg and Baseline platelet count of >=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
Study NCT03326193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
Study NCT03390933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
Study NCT03868735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanSweep Closed Suction System
Description: Device with balloon sweeping technology
Study NCT00278148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily
Study NCT00278148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 50mg/m2/weekly x 3 weeks
Study NCT00278148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: conventional surgery
Study NCT00278148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 150 cGy bid
Study NCT02603068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
Study NCT02634268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Behavioral lifestyle intervention focused on healthy eating and physical activity
Study NCT03603951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
Study NCT00072436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00072436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00072436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02813447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study NCT02813447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00439348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal advice
Description: Patients receive verbal advice regarding specific over-the-counter medications.
Study NCT00439348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription
Description: Patients receive a prescription for a specific over-the-counter medication.
Study NCT00672763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol D3 (Vigantol Oil)
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses).
Study NCT00672763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medium chain triglycerides
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)
Study NCT00676195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day
Study NCT02548754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym device
Study NCT02548754 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Parasym device
Study NCT04656197 — intervention group
Intervention type: OTHER
Intervention: Ocular microbiome
Description: Taxonomical and functional characterization of the ocular microbiome
Study NCT03420807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHRC
Description: Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
Study NCT01294007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PureGen Osteoprogenitor Cell Allograft
Description: PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
Study NCT01294007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft bone
Description: Iliac Crest and Local Autograft Bone
Study NCT00318851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Stent with Distal Protection Device
Description: Carotid Stent Placement with Distal Protection
Study NCT02686242 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: bupivacaine injected by spinal puncture
Study NCT02686242 — intervention group
Intervention type: PROCEDURE
Intervention: general anesthesia
Description: general anesthesia with intubation
Study NCT00904202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules + Placebo Patch
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Study NCT00904202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules + Lidoderm®
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Study NCT00904202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin + Placebo
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Study NCT00904202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin + Lidoderm®
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
Study NCT00904202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Description: Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Study NCT00904202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin 1800 mg/day + Lidoderm patch
Study NCT04955665 — intervention group
Intervention type: PROCEDURE
Intervention: bone block procedure
Description: a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
Study NCT04955665 — intervention group
Intervention type: PROCEDURE
Intervention: Reattachment of the superior peroneal retinaculum
Description: two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
Study NCT04000698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative regimen
Description: Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes
Study NCT04612881 — intervention group
Intervention type: DRUG
Intervention: fitostimoline vaginal pessaries
Description: vaginal pessaries
Study NCT04612881 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: standard of care
Study NCT02191176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan syrup - low dose
Study NCT02191176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan syrup - high dose
Study NCT02191176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01447446 — intervention group
Intervention type: DRUG
Intervention: Peg-IFN Alfa-2a
Description: Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
Study NCT01447446 — intervention group
Intervention type: DRUG
Intervention: Peg-IFN Alfa-2b
Description: Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
Study NCT01447446 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.
Study NCT01447446 — intervention group
Intervention type: DRUG
Intervention: Boceprevir
Description: Boceprevir according to standard of care and in line with local labeling.
Study NCT01447446 — intervention group
Intervention type: DRUG
Intervention: Telaprevir
Description: Telaprevir according to standard of care and in line with local labeling.